Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133128110> ?p ?o ?g. }
- W3133128110 endingPage "212" @default.
- W3133128110 startingPage "201" @default.
- W3133128110 abstract "Abstract Mutations in the BRAF gene are highly prevalent in thyroid cancer. However, the response rate of thyroid tumors to BRAF‐directed therapies has been mixed. Increasingly, combination therapies inhibiting the MAPK pathway at multiple nodes have shown promise. Recently developed ERK1/2 inhibitors are of interest for use in combination therapies as they have the advantage of inhibiting the most downstream node of the MAPK pathway, therefore preventing pathway reactivation. Here, we examined the effect of combined BRAF inhibition (dabrafenib) and ERK1/2 inhibition (SCH772984) on the growth and survival of a panel of BRAF ‐mutant thyroid cancer cell lines using in vitro and in vivo approaches. We found that resistance due to MAPK pathway reactivation occurs quickly with single‐agent BRAF inhibition, but can be prevented with combined BRAF and ERK1/2 inhibition. Combined inhibition also results in synergistic growth inhibition, decreased clonogenic survival, and enhanced induction of apoptosis in a subset of BRAF ‐mutant thyroid cancer cells. Finally, combined inhibition of BRAF and ERK1/2 results in enhanced inhibition of tumor growth in an anaplastic thyroid cancer in vivo model. These results provide key rationale to pursue combined BRAF and ERK1/2 inhibition as an alternative therapeutic strategy for BRAF ‐mutant advanced thyroid cancer patients." @default.
- W3133128110 created "2021-03-01" @default.
- W3133128110 creator A5018764559 @default.
- W3133128110 creator A5023876983 @default.
- W3133128110 creator A5029491331 @default.
- W3133128110 creator A5033726382 @default.
- W3133128110 creator A5058493119 @default.
- W3133128110 creator A5060523730 @default.
- W3133128110 creator A5062004692 @default.
- W3133128110 creator A5066515599 @default.
- W3133128110 creator A5080362625 @default.
- W3133128110 creator A5085475958 @default.
- W3133128110 date "2021-02-17" @default.
- W3133128110 modified "2023-10-16" @default.
- W3133128110 title "Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth <i>in vitro</i> and <i>in vivo</i>" @default.
- W3133128110 cites W1821265034 @default.
- W3133128110 cites W1916509051 @default.
- W3133128110 cites W1965370740 @default.
- W3133128110 cites W1967947358 @default.
- W3133128110 cites W1968940692 @default.
- W3133128110 cites W1977889509 @default.
- W3133128110 cites W1983712256 @default.
- W3133128110 cites W1990196512 @default.
- W3133128110 cites W1990511191 @default.
- W3133128110 cites W1996947212 @default.
- W3133128110 cites W2013518349 @default.
- W3133128110 cites W2024085992 @default.
- W3133128110 cites W2026186449 @default.
- W3133128110 cites W2040286515 @default.
- W3133128110 cites W2043058822 @default.
- W3133128110 cites W2069792474 @default.
- W3133128110 cites W2070645893 @default.
- W3133128110 cites W2072860434 @default.
- W3133128110 cites W2077945404 @default.
- W3133128110 cites W2097112996 @default.
- W3133128110 cites W2100614336 @default.
- W3133128110 cites W2104602638 @default.
- W3133128110 cites W2105660237 @default.
- W3133128110 cites W2108668400 @default.
- W3133128110 cites W2116386978 @default.
- W3133128110 cites W2120687938 @default.
- W3133128110 cites W2122181910 @default.
- W3133128110 cites W2128542677 @default.
- W3133128110 cites W2129398950 @default.
- W3133128110 cites W2141674733 @default.
- W3133128110 cites W2149000868 @default.
- W3133128110 cites W2154817142 @default.
- W3133128110 cites W2157633567 @default.
- W3133128110 cites W2160766792 @default.
- W3133128110 cites W2171367970 @default.
- W3133128110 cites W2179395367 @default.
- W3133128110 cites W2211890826 @default.
- W3133128110 cites W2290466312 @default.
- W3133128110 cites W2397338957 @default.
- W3133128110 cites W2409383155 @default.
- W3133128110 cites W2409901341 @default.
- W3133128110 cites W2491982852 @default.
- W3133128110 cites W2503674037 @default.
- W3133128110 cites W2528756267 @default.
- W3133128110 cites W2555358355 @default.
- W3133128110 cites W2590873467 @default.
- W3133128110 cites W2592322879 @default.
- W3133128110 cites W2593388782 @default.
- W3133128110 cites W2728615743 @default.
- W3133128110 cites W2736254713 @default.
- W3133128110 cites W2760461398 @default.
- W3133128110 cites W2766581537 @default.
- W3133128110 cites W2768523107 @default.
- W3133128110 cites W2769724680 @default.
- W3133128110 cites W2774483419 @default.
- W3133128110 cites W2886191746 @default.
- W3133128110 cites W2890752806 @default.
- W3133128110 cites W3005662902 @default.
- W3133128110 cites W3091722685 @default.
- W3133128110 doi "https://doi.org/10.1002/mc.23284" @default.
- W3133128110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33595872" @default.
- W3133128110 hasPublicationYear "2021" @default.
- W3133128110 type Work @default.
- W3133128110 sameAs 3133128110 @default.
- W3133128110 citedByCount "10" @default.
- W3133128110 countsByYear W31331281102021 @default.
- W3133128110 countsByYear W31331281102022 @default.
- W3133128110 countsByYear W31331281102023 @default.
- W3133128110 crossrefType "journal-article" @default.
- W3133128110 hasAuthorship W3133128110A5018764559 @default.
- W3133128110 hasAuthorship W3133128110A5023876983 @default.
- W3133128110 hasAuthorship W3133128110A5029491331 @default.
- W3133128110 hasAuthorship W3133128110A5033726382 @default.
- W3133128110 hasAuthorship W3133128110A5058493119 @default.
- W3133128110 hasAuthorship W3133128110A5060523730 @default.
- W3133128110 hasAuthorship W3133128110A5062004692 @default.
- W3133128110 hasAuthorship W3133128110A5066515599 @default.
- W3133128110 hasAuthorship W3133128110A5080362625 @default.
- W3133128110 hasAuthorship W3133128110A5085475958 @default.
- W3133128110 hasConcept C117262875 @default.
- W3133128110 hasConcept C121608353 @default.
- W3133128110 hasConcept C134018914 @default.
- W3133128110 hasConcept C190283241 @default.